ATH-1017 + Placebo

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 25/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Alzheimer Disease

Conditions

Alzheimer Disease, Dementia of Alzheimer Type

Trial Timeline

Nov 23, 2020 → May 20, 2022

NCT ID

NCT04491006

About ATH-1017 + Placebo

ATH-1017 + Placebo is a phase 2 stage product being developed by LeonaBio for Alzheimer Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT04491006. Target conditions include Alzheimer Disease, Dementia of Alzheimer Type.

What happened to similar drugs?

20 of 20 similar drugs in Alzheimer Disease were approved

Approved (20) Terminated (2) Active (0)

✅Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab.YuhanApproved

✅DonepezilEisaiApproved

✅DONEPEZIL HYDROCHLORIDEEisaiApproved

✅Donepezil HCLEisaiApproved

✅Donepezil HClEisaiApproved

✅Donepezil HydrochlorideEisaiApproved

✅AriceptEisaiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04831281	Phase 2	Terminated	Jan 20, 2022	Apr 19, 2023	Parkinson Disease Dementia
NCT04491006	Phase 2	Completed	Nov 23, 2020	May 20, 2022	Alzheimer Disease
NCT04488419	Phase 2/3	Completed	Sep 28, 2020	Jul 15, 2024	Alzheimer Disease

Competing Products

20 competing products in Alzheimer Disease

See all competitors

Product	Company	Stage	Hype Score
[18F]NAV4694	Navidea Biopharmaceuticals	Phase 2	21
Bromocriptine Mesilate + Placebos	Towa Pharmaceutical	Phase 1/2	32
LY450139 + Placebo	Eli Lilly	Phase 3	40
Solanezumab + Placebo	Eli Lilly	Phase 3	32
LY450139 dihydrate + placebo	Eli Lilly	Phase 2	35
Zagotenemab + Placebo	Eli Lilly	Phase 2	35
Donanemab + Placebo + LY3202626	Eli Lilly	Phase 2	35
Donanemab + Placebo	Eli Lilly	Phase 3	47
GSK4527226	Alector	Phase 2	29
AL002 + Placebo	Alector	Phase 2	25
GSK4527226	Alector	Phase 2	32
AL002	Alector	Phase 2	17
Solanezumab + Placebo	Eli Lilly	Phase 3	32
donanemab	Eli Lilly	Phase 2	35
ATH-1017	LeonaBio	Phase 2/3	20
ATH-1017 + Placebo	LeonaBio	Phase 2/3	28
NDX-1017 + Placebo	LeonaBio	Phase 1	19
simufilam	Cassava Sciences	Phase 2	17
50 mg PTI-125 + 100 mg PTI-125 + 200 mg PTI-125	Cassava Sciences	Phase 1	19
Placebo oral tablet + Simufilam 100 mg tablet + Simufilam 50 mg oral tablet	Cassava Sciences	Phase 2	25